Business Cases & Investment Decisions
The case for a specific investment: the need, alternatives considered, benefits, costs, risk, timing, stated assumptions, approval gates, and who owns delivering the promised outcome. A business case is a set of assumptions that become commitments. Where the quality and regulatory assumptions are optimistic — a shorter qualification, a lighter validation, an easier variation — the shortfall is absorbed later by the functions that were not consulted.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSA business case is a set of assumptions that become commitments, and the optimistic ones are usually absorbed by functions never asked — most often the ones that qualify, validate and test.
06 · QUALITY MATURITY — BUSINESS CASES & INVESTMENT DECISIONS, REACTIVE TO ADAPTIVE
Cases are built by their sponsors. Timelines and resource assumptions are optimistic and nobody outside the project tests them.
A standard template and approval process exist, and quality signs the case without having supplied the assumptions that concern it.
Assumptions affecting quality and validation are supplied by the functions that will meet them, and the ongoing obligation is counted alongside the capital.
Alternatives are appraised including the one nobody writes down — doing nothing — and benefits carry an owner who remains after approval.
Realised benefit is measured against the case, and what the comparison shows changes how the next case is built.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: ICH, ASTM, ISO.
RECORDS & OBJECTIVE EVIDENCE
- Business cases with their assumptions, and who supplied each
- The ongoing regulatory and quality obligation the investment creates
- Alternatives appraised, including the do-nothing option
- Named benefit owners persisting past approval
- Post-implementation reviews comparing realised benefit against the case
COMMON INSPECTION FINDINGS
- Timelines committed without the functions that must meet them being consulted
- Ongoing qualification, monitoring and revalidation cost absent from the case
- A single option appraised, so approval was a formality
- Benefits with no owner after approval, so realisation is nobody’s task
- No post-implementation review, so the same optimistic assumptions recur
The assumptions that are systematically optimistic
Investment cases in regulated industry contain a recognisable set of assumptions that trend one way: qualification will take one cycle, validation will be lighter than the last time, the variation will be a notification rather than a prior approval, the technology transfer will not need a bridging study, and the new system will be validated in the quoted implementation timeline. Each is possible; collectively they are a forecast at the optimistic edge of every distribution.
The countermeasure is not pessimism but attribution: name the assumption, name the function that owns it, and have that function state the range rather than the point. A regulatory affairs group asked whether a change is a notification will usually say it depends and explain on what — which is more useful than the single-value assumption the model needs and gets anyway.
Alternatives, including the one nobody writes down
A case that considers only the proposed investment and doing nothing has not evaluated alternatives. The comparison that most often changes the answer is the smaller intervention: fixing the process rather than buying capacity around it, remediating the existing system rather than replacing it, or improving right-first-time rather than adding a shift.
These lose on presentation. A capital purchase has a defined scope, a vendor and a date; a process-improvement alternative has none of those and looks unfundable next to it, even where the return is better and faster. Requiring the improvement alternative to be costed in every capacity case is a small procedural rule that reliably surfaces cheaper answers.
Benefit ownership after approval
Business cases are approved on projected benefit and are almost never revisited to establish whether it arrived. The consequence compounds: an organisation with no benefit-realisation discipline cannot distinguish the investments that worked from those that did not, so its next case is argued on the same basis as the last one and the estimation never improves.
The fix is to name a benefit owner who is not the project manager — the person accountable for the outcome once the project has closed — and a defined check at a stated interval afterwards. It is uncomfortable for exactly the reason it is valuable, and it is the only mechanism by which an organisation’s forecasting gets better.
SPEQ interpretation — count the ongoing obligation, not just the capital
Every regulated investment creates a permanent operating obligation the case rarely quantifies: a system to periodically review, equipment to requalify, methods to maintain, a supplier to re-audit, records to retain. These are small individually and cumulative across a portfolio, and they land on functions whose headcount was set before the investment.
Adding a line to the case — the annual quality-organisation effort this creates — changes two things. It makes the total cost honest, and it makes the accumulation visible, which is what eventually justifies the retirement of something else. An estate that only ever grows does so because nothing ever counted what growth costs to maintain.
FREQUENTLY ASKED
Which business-case assumptions are systematically optimistic?
Qualification in one cycle, lighter validation than last time, a notification rather than a prior-approval variation, a transfer without a bridging study, and system validation inside the vendor implementation timeline. Each is possible; together they sit at the optimistic edge of every distribution, and the shortfall lands on functions that were not consulted.
What alternative is usually missing from a capacity case?
The smaller intervention — fixing the process rather than buying capacity around it, remediating rather than replacing, improving right-first-time rather than adding a shift. It loses on presentation because it has no vendor, scope or date, even where the return is better and faster. Requiring it to be costed reliably surfaces cheaper answers.
Why does benefit realisation matter beyond accountability?
Because without it an organisation cannot distinguish investments that worked from those that did not, so the next case is argued on the same basis as the last and estimation never improves. A named benefit owner who is not the project manager, with a check at a stated interval, is the only mechanism that improves forecasting.
What ongoing cost do investment cases omit?
The permanent quality obligation: a system to review periodically, equipment to requalify, methods to maintain, a supplier to re-audit, records to retain. Small individually, cumulative across a portfolio, and landing on functions whose headcount was set before the investment. Counting it also makes the case for retiring something else.